Advertisement

Clinical Rheumatology

, Volume 36, Issue 5, pp 1023–1029 | Cite as

Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China

  • Chun Li
  • X. R. Wang
  • H. J. Ji
  • X. Y. Zhang
  • X. F. Li
  • L. Z. Wang
  • C. H. Wang
  • Y. F. Wang
  • Rong Yang
  • G. C. Wang
  • Xin Lu
  • Ping Zhu
  • L. N. Chen
  • H. T. Jin
  • J. T. Liu
  • X. Y. Liu
  • Lin Sun
  • H. Y. Chen
  • Ping Wei
  • J. X. Wang
  • L. F. Cui
  • Rong Shu
  • B. L. Liu
  • Z. L. Zhang
  • G. T. Li
  • Z. B. Li
  • Jing Yang
  • J. F. Li
  • Bin Jia
  • F. X. Zhang
  • J. M. Tao
  • S. L. Han
  • J. Y. Lin
  • M. Q. Wei
  • X. M. Liu
  • Dan Ke
  • S. X. Hu
  • Cong Ye
  • X. Y. Yang
  • Hao Li
  • C. B. Huang
  • Ming Gao
  • Bei Lai
  • X. F. Li
  • L. J. Song
  • Yi Wang
  • X. Y. Wang
  • Y. D. Tang
  • Yin Su
  • Rong Mu
  • Z. G. Li
Original Article

Abstract

This study aims to assess the risk factors of cardiovascular disease (CVD) and to determine the association of traditional and biologic disease-modifying anti-rheumatic drugs (DMARDs) with risk for CVD in Chinese rheumatoid arthritis (RA) patients. A cross-sectional cohort of 2013 RA patients from 21 hospitals around China was established. Medical history of CVD was documented. The patients’ social background, clinical manifestations, comorbidities, and medications were also collected. Of the 2013 patients, 256 had CVD with an incidence of 12.7%. Compared with non-CVD controls, RA patients with CVD had a significantly advanced age, long-standing median disease duration, more often male and more deformity joints. Patients with CVD also had higher rates of smoking, rheumatoid nodules, interstitial lung disease, and anemia. The prevalence of comorbidities, including hypothyroidism, diabetes mellitus (DM), hypertension, and hyperlipidemia, was also significant higher in the CVD group. In contrast, patients treated with methotrexate, hydroxychloroquine (HCQ), and TNF blockers had lower incidence of CVD. The multivariate analysis showed that the use of HCQ was a protective factor of CVD, while hypertension, hyperlipidemia, and interstitial lung disease were independent risk factors of CVD. Our study shows that the independent risk factors of CVD include hypertension, hyperlipidemia, and interstitial lung disease. HCQ reduces the risk of CVD in patients with RA.

Keywords

Cardiovascular disease Rheumatoid arthritis Risk factor 

Notes

Acknowledgments

We are very grateful to the patients and their families for their cooperation and for giving consent to participate in this study.

Compliance with ethical standards

The study was approved by the Ethics Committee of Peking University People’s Hospital, and informed written consents were obtained from all study participants (FWA00001384).

Disclosures

None.

Funding

Supported by National High Technology Research and Development Program of China (973 Program, 2012CB517700) and National Natural Science Foundation of China (NSFC, No. 81202297)

References

  1. 1.
    Sokka T, Abelson B, Pincus T (2008) Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 26:S35–S61PubMedGoogle Scholar
  2. 2.
    Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O’Fallon WM, Matteson EL (2003) Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 48:54–58CrossRefPubMedGoogle Scholar
  3. 3.
    Gonzalez A, Maradit KH, Crowson CS, Ballman KV, Roger VL, Jacobsen SJ, O’Fallon WM, Gabriel SE (2008) Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients. Ann Rheum Dis 67:64–69CrossRefPubMedGoogle Scholar
  4. 4.
    Pham T, Gossec L, Constantin A, Pavy S, Bruckert E, Cantagrel A, Combe B, Flipo RM, Goupille P, Le LX, Mariette X, Puechal X, Schaeverbeke T, Sibilia J, Tebib J, Wendling D, Dougados M (2006) Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 73:379–387CrossRefPubMedGoogle Scholar
  5. 5.
    Restrepo JF, Del RI, Battafarano DF, Haas RW, Doria M, Escalante A (2015) Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis. Clin Rheumatol 34(9):1529–1536CrossRefPubMedGoogle Scholar
  6. 6.
    Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, McInnes IB, Haentzschel H, Gonzalez-Gay MA, Provan S, Semb A, Sidiropoulos P, Kitas G, Smulders YM, Soubrier M, Szekanecz Z, Sattar N, Nurmohamed MT (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325–331CrossRefPubMedGoogle Scholar
  7. 7.
    Crowson CS, Gabriel SE (2011) Towards improving cardiovascular risk management in patients with rheumatoid arthritis: the need for accurate risk assessment. Ann Rheum Dis 70:719–721CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Dessein PH, Semb AG (2013) Could cardiovascular disease risk stratification and management in rheumatoid arthritis be enhanced. Ann Rheum Dis 72:1743–1746CrossRefPubMedGoogle Scholar
  9. 9.
    Arts EE, Popa C, Den BAA, Semb AG, Toms T, Kitas GD, van Riel PL, Fransen J (2014) Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis 74:668–674CrossRefPubMedGoogle Scholar
  10. 10.
    van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE (2006) Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 8:R151CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Avouac J, Allanore Y (2008) Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opin Pharmacother 9:1121–1128CrossRefPubMedGoogle Scholar
  12. 12.
    Bili A, Tang X, Pranesh S, Bozaite R, DO SJ, Antohe JL, Kirchner HL, Wasko MC (2013) TNF-alpha inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 66:355–363.Google Scholar
  13. 13.
    Davis JM 3rd, Maradit KH, Crowson CS, Nicola PJ, Ballman KV, Therneau TM, Roger VL, Gabriel SE (2007) Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 56:820–830CrossRefPubMedGoogle Scholar
  14. 14.
    Rodriguez-Rodriguez L, Gonzalez-Juanatey C, Palomino-Morales R, Vazquez-Rodriguez TR, Miranda-Filloy JA, Fernandez-Gutierrez B, Llorca J, Martin J, Gonzalez-Gay MA (2011) TNFA -308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 216:125–130CrossRefPubMedGoogle Scholar
  15. 15.
    van Halm VP, Peters MJ, Voskuyl AE, Boers M, Lems WF, Visser M, Stehouwer CD, Spijkerman AM, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Smulders YM, Dijkmans BA, Nurmohamed MT (2009) Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 68:1395–1400CrossRefPubMedGoogle Scholar
  16. 16.
    (1997) The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157:2413–2446Google Scholar
  17. 17.
    Bobbio-Pallavicini F, Caporali R, Bugatti S, Montecucco C (2008) What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated peptide antibodies. J Rheumatol 35:1903–1905PubMedGoogle Scholar
  18. 18.
    World Health Organization Western Pacific Region/IASO/IOTF (2000) The Asia–Pacific perspective: redefining obesity and its treatment. SydneyGoogle Scholar
  19. 19.
    Goodson NJ, Farragher TM, Symmons DP (2008) Rheumatoid factor, smoking, and disease severity: associations with mortality in rheumatoid arthritis. J Rheumatol 35:945–949PubMedGoogle Scholar
  20. 20.
    Erb N, Pace AV, Douglas KM, Banks MJ, Kitas GD (2004) Risk assessment for coronary heart disease in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 33:293–299CrossRefPubMedGoogle Scholar
  21. 21.
    Toms TE, Panoulas VF, Douglas KM, Griffiths H, Sattar N, Smith JP, Symmons DP, Nightingale P, Metsios GS, Kitas GD (2010) Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk. Ann Rheum Dis 69:683–688CrossRefPubMedGoogle Scholar
  22. 22.
    Steiner G, Urowitz MB (2009) Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum 38:372–381CrossRefPubMedGoogle Scholar
  23. 23.
    Sandoo A, Chanchlani N, Hodson J, Smith JP, Douglas KM, Kitas GD (2013) Classical cardiovascular disease risk factors associate with vascular function and morphology in rheumatoid arthritis: a six-year prospective study. Arthritis Res Ther 15:R203CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Chung CP, Giles JT, Kronmal RA, Post WS, Gelber AC, Petri M, Szklo M, Detrano R, Budoff MJ, Blumenthal RS, Ouyang P, Bush D, Bathon JM (2013) Progression of coronary artery atherosclerosis in rheumatoid arthritis: comparison with participants from the Multi-Ethnic Study of Atherosclerosis. Arthritis Res Ther 15:R134CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Koduri G, Norton S, Young A, Cox N, Davies P, Devlin J, Dixey J, Gough A, Prouse P, Winfield J, Williams P (2010) Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford) 49:1483–1489CrossRefGoogle Scholar
  26. 26.
    Morris SJ, Wasko MC, Antohe JL, Sartorius JA, Kirchner HL, Dancea S, Bili A (2011) Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 63:530–534CrossRefGoogle Scholar
  27. 27.
    Anigbogu CN, Adigun SA, Inyang I, Adegunloye BJ (1993) Chloroquine reduces blood pressure and forearm vascular resistance and increases forearm blood flow in healthy young adults. Clin Physiol 13:209–216CrossRefPubMedGoogle Scholar
  28. 28.
    Penn SK, Kao AH, Schott LL, Elliott JR, Toledo FG, Kuller L, Manzi S, Wasko MC (2010) Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 37:1136–1142CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Dessein PH, Joffe BI (2006) Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 54:2765–2775CrossRefPubMedGoogle Scholar
  30. 30.
    Quatraro A, Consoli G, Magno M, Caretta F, Nardozza A, Ceriello A, Giugliano D (1990) Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug. Ann Intern Med 112:678–681CrossRefPubMedGoogle Scholar
  31. 31.
    Petri M (1996) Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 5(Suppl 1):S16–S22CrossRefPubMedGoogle Scholar
  32. 32.
    Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, Ward MM (2007) Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 298:187–193CrossRefPubMedGoogle Scholar
  33. 33.
    Weissberg PL, Bennett MR (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340:1928–1929CrossRefPubMedGoogle Scholar
  34. 34.
    Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74:480–489CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Solomon DH, Curtis JR, Saag KG, Lii J, Chen L, Harrold LR, Herrinton LJ, Graham DJ, Kowal MK, Kuriya B, Liu L, Griffin MR, Lewis JD, Rassen JA (2013) Cardiovascular risk in rheumatoid arthritis: comparing TNF-alpha blockade with nonbiologic DMARDs. Am J Med 126(730):e9-730–e9-e17Google Scholar
  36. 36.
    Mathieu S, Pereira B, Dubost JJ, Lusson JR, Soubrier M (2012) No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment. Rheumatology (Oxford) 51:1107–1111CrossRefGoogle Scholar
  37. 37.
    Choy E, Sattar N (2009) Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 68:460–469CrossRefPubMedGoogle Scholar
  38. 38.
    Rao VU, Pavlov A, Klearman M, Musselman D, Giles JT, Bathon JM, Sattar N, Lee JS (2015) An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheumatol 67:372–380CrossRefPubMedGoogle Scholar
  39. 39.
    Ursini F, Russo E, Letizia HM, Mauro D, Savarino F, Bruno C, Tripolino C, Rubino M, Naty S, Grembiale RD (2015) Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study. Medicine (Baltimore) 94:e888CrossRefGoogle Scholar
  40. 40.
    Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR, Diaz-Varela N, Garcia-Quiroga H, Gonzalez-Gay MA (2008) Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum 59:1821–1824CrossRefPubMedGoogle Scholar
  41. 41.
    Liao KP, Solomon DH (2013) Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford) 52:45–52CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2017

Authors and Affiliations

  • Chun Li
    • 1
  • X. R. Wang
    • 2
  • H. J. Ji
    • 1
  • X. Y. Zhang
    • 1
  • X. F. Li
    • 3
  • L. Z. Wang
    • 3
  • C. H. Wang
    • 3
  • Y. F. Wang
    • 4
  • Rong Yang
    • 4
  • G. C. Wang
    • 5
  • Xin Lu
    • 5
  • Ping Zhu
    • 6
  • L. N. Chen
    • 6
  • H. T. Jin
    • 7
  • J. T. Liu
    • 7
  • X. Y. Liu
    • 8
  • Lin Sun
    • 8
  • H. Y. Chen
    • 9
  • Ping Wei
    • 9
  • J. X. Wang
    • 9
  • L. F. Cui
    • 10
  • Rong Shu
    • 10
  • B. L. Liu
    • 10
  • Z. L. Zhang
    • 11
  • G. T. Li
    • 11
  • Z. B. Li
    • 12
  • Jing Yang
    • 12
  • J. F. Li
    • 13
  • Bin Jia
    • 13
  • F. X. Zhang
    • 14
  • J. M. Tao
    • 14
  • S. L. Han
    • 2
  • J. Y. Lin
    • 15
  • M. Q. Wei
    • 15
  • X. M. Liu
    • 16
  • Dan Ke
    • 16
  • S. X. Hu
    • 17
  • Cong Ye
    • 17
  • X. Y. Yang
    • 18
  • Hao Li
    • 18
  • C. B. Huang
    • 19
  • Ming Gao
    • 19
  • Bei Lai
    • 19
  • X. F. Li
    • 20
  • L. J. Song
    • 20
  • Yi Wang
    • 21
  • X. Y. Wang
    • 21
  • Y. D. Tang
    • 22
  • Yin Su
    • 1
  • Rong Mu
    • 1
  • Z. G. Li
    • 1
  1. 1.Department of Rheumatology and ImmunologyPeking University People’s HospitalBeijingChina
  2. 2.Department of Rheumatology and ImmunologyPeking University Shougang HospitalBeijingChina
  3. 3.Department of Rheumatology and ImmunologyThe Second Affiliated Hospital Shanxi Medical UniversityTaiyuanChina
  4. 4.Department of Rheumatology and ImmunologyThe First Affiliated Hospital, Baotou Medical CollegeBaotouChina
  5. 5.Department of Rheumatology and ImmunologyChina-Japan Friendship HospitalBeijingChina
  6. 6.Department of Rheumatology and ImmunologyXijing HospitalXianChina
  7. 7.Department of Rheumatology and ImmunologyThe Second Hospital of Hebei Medical UniversityShijiazhuangChina
  8. 8.Department of Rheumatology and ImmunologyPeking University Third HospitalBeijingChina
  9. 9.Department of Rheumatology and ImmunologyThe Third Hospital of Hebei Medical UniversityShijiazhuangChina
  10. 10.Department of Rheumatology and ImmunologyKailuan Hospital of North China Coal HospitalTangshanChina
  11. 11.Department of Rheumatology and ImmunologyPeking University First HospitalBeijingChina
  12. 12.Department of Rheumatology and ImmunologyPeace HospitalShijiazhuangChina
  13. 13.Department of Rheumatology and ImmunologyHebei Handan Central HospitalHandanChina
  14. 14.Department of Rheumatology and ImmunologyHebei People’s HospitalShijiazhuangChina
  15. 15.Department of Rheumatology and ImmunologyThe People’s Hospital of Guangxi Zhuang Autonomous RegionNanningChina
  16. 16.Department of Rheumatology and ImmunologyBeijing Shunyi Hospital of China Medical UniversityBeijingChina
  17. 17.Department of Rheumatology and ImmunologyTongji Medical College Huazhong University of Science and TechnologyWuhanChina
  18. 18.Department of Rheumatology and ImmunologyFirst Affiliated Hospital of Sun Yat-sen UniversityGuangzhouChina
  19. 19.Department of Rheumatology and ImmunologyBeijing HospitalBeijingChina
  20. 20.Department of Rheumatology and ImmunologyQilu Hospital of Shandong UniversityJinanChina
  21. 21.Department of Rheumatology and ImmunologySecond Hospital of Lanzhou UniversityLanzhouChina
  22. 22.Department of CardiologyFuwai HospitalBeijingChina

Personalised recommendations